Correlation of C1q/TNF-Related Protein-3 with Cardiac Autonomic Tone and Metabolic Parameters in Obesity

Neha Bindlish Jain 1, Asha Yadav 1,*, Nilima Shankar 1 and Rafat Ahmed 2

1Department of Physiology, University College of Medical Sciences, Delhi, India
2Department of Biochemistry, University College of Medical Sciences, Delhi, India

*Corresponding author: Department of Physiology, University College of Medical Sciences, Delhi, India. Email: drashayadav@yahoo.co.in

Abstract

Objectives: The current study aimed at investigating the correlation of circulating levels of serum C1q/TNF-related protein-3 (CTRP3) with cardiac autonomic functions and metabolic parameters in obesity.

Methods: Thirty drug naïve subjects newly diagnosed with obesity and body mass index (BMI) 25 - 35 kg/m² of both genders aged 19 - 40 years, with no associated comorbidity were recruited as cases. Same number of age, gender and socioeconomic status matched subjects with BMI 19 - 23 kg/m² were taken as controls. Autonomic function test results including heart rate variability (HRV) were recorded in both groups. Serum metabolic parameters - CTRP3, leptin, adiponectin, insulin, blood glucose, glycated hemoglobin (HbA1c), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides were also determined and compared between the groups.

Results: Significantly lower circulating levels of CTRP3 (P ≤ 0.001) and adiponectin (P = 0.025), and significantly higher mean of BMI (P < 0.001), fasting blood glucose (P < 0.001), LDL-cholesterol (P < 0.05), serum triglycerides (P < 0.001), insulin (P = 0.003), HOMA-IR (homeostasis model assessment of insulin resistance) (P < 0.001), and leptin (P = 0.043) were observed in the group with obesity compared to the controls. CTRP3 levels inversely correlated with serum triglyceride (r = -0.09, P < 0.001), atherogenic index (r = -0.37, P = 0.04), leptin (r = -0.39, P = 0.02), and positively with adiponectin (r = 0.42, P = 0.02) in the group with obesity. Significant reduction in the results of parasympathetic autonomic function tests (pNN50, RMSSD, excitation: inhibition (E:I) ratio, 30:15 ratio, and Valsalva ratio) and an increase in sympathovagal balance (low frequency to high frequency (LF:HF) ratio) was also observed (P < 0.05). CTRP3 levels were also positively correlated with parasympathetic indices (pNN50: r = 0.17, P < 0.05); 30:15 ratio: (r = 0.62, P < 0.01), and inversely correlated with LF:HF ratio (r = -0.35, P < 0.01) in the group with obesity.

Conclusions: Higher circulating levels of CTRP3 promoted a favorable autonomic and metabolic profile in obesity. Hence, CTRP3 may be considered as a potential novel biomarker to facilitate the prognosis of obesity and its comorbidities.

Keywords: CTRP3, Obesity, Autonomic Functions, Metabolic Parameters

1. Background

Adipose tissue is now emerging as a unique active endocrine organ secreting various adipokines. The complement C1q tumor necrosis factor-related protein 3 (CTRP3), adiponectin, tumor necrosis factor alpha (TNF-alpha), as well as other proteins with distinct C1q domain are collectively grouped as C1q/TNF superfamily. CTRP3 is one of the novel adipokines acknowledged as an anti-inflammatory, anti-apoptotic, pro-angiogenic, and cardioprotective molecule, with numerous anti-diabetic properties according to various studies conducted in diet-induced obese mouse models (1-4). Previous studies suggest that CTRP3 is the closest functional homologue of adiponectin, which has an important role in inflammation and metabolism (5, 6).

In particular, CTRP3 attracted a great attention in recent years especially in glycolipid metabolism and pathogenesis of cardiovascular diseases. Cardiovascular function can be non-invasively reflected by the autonomic functions disturbed in cardiovascular diseases leading to mortality (7). Decreased cardiac vagal outflow in obesity may be contributed to chronic hyperinsulinemia (7). Sympathetic overactivity in obesity is likely to be multifactorial and adipokines play a fundamental role amongst all of them (8-10). The components of the metabolic syndrome that may directly or indirectly enhance sympathetic drive include hyperinsulinemia, leptin, non-esterified fatty acids, and pro-inflammatory cytokines (11).
Sympathetic overdrive may be a common thread to the functional evolution of metabolic syndrome and its consequences. In several clinical adult populations, a negative association is demonstrated between adiponectin and sympathetic activity, as well as a positive association with parasympathetic activity. However, there is ambiguity in results with regards to the association between the autonomic balance and leptin (12-15). Heart rate variability (HRV) is a good tool to quantify the tone of autonomic nervous system to the myocardium called the cardiac autonomic tone (16).

Compared with other adipocytes, there is still a paucity of data with conflicting results about the role of CTRP3 in metabolic syndrome, systemic inflammation, and Insulin resistance (17-21). The potential use of circulating CTRP3 levels as a biomarker for risk or the presence of cardiovascular disease is not yet established. Moreover, to the best of authors’ knowledge, no study explored the clinical correlation of CTRP3 with autonomic functions in obesity yet. This motivated the authors to study the clinical characteristics of CTRP3 with autonomic and metabolic parameters in obesity, understand their complex interplay in the body, and work together and independently.

2. Objectives

The current study aimed at assessing and correlating CTRP3 levels with the metabolic and autonomic parameters in obesity.

3. Methods

3.1. Study Design

The current retrospective, analytical, case-control study was conducted from October 2015 to April 2017, in a tertiary care community hospital in India. It was a non-randomized study with convenient sampling strategy; since the subjects were recruited from the general population based on their body mass index (BMI). The studied outcome measures were serum CTRP3, fasting metabolic parameters, and cardiac autonomic function tests including HRV in both groups.

Prior written informed consent was obtained from all subjects explaining the duration, type, and objectives of the study. Ethical clearance was obtained for the study from the Institutional Research Protocol and Ethics Committee Board.

3.2. Subjects

The study design was consistent with the emphasis made by World Health Organization (WHO) Western Pacific Regional Office to use BMI > 25 kg/m² as a new cut-off point to redefine obesity in the Indian population (21). Newly diagnosed treatment/drug naïve subjects with BMI 25-35 kg/m², without comorbidity, smoke, and alcohol consumption were included in the study group as cases (group I, n = 30) and the same number of age-, gender-, and socioeconomic-status-matched subjects with BMI 19-23 kg/m² were taken as controls (group II, n = 30). Subjects with diabetes mellitus, hypertension, or any other chronic illness such as malignancy, tuberculosis, hepatic or renal disease, any clinically proven endocrine disorders pertaining to obesity such as hypothyroidism, the Cushing syndrome, polycystic ovarian syndrome (PCOS), pregnant/lactating females, history of weight loss surgery, long-term medications such as steroids, weight loss intervention, oral contraceptive pills, and history of substance abuse were excluded from the study.

Autonomic functions, metabolic parameters, and CTRP3 levels were assessed in both groups under similar laboratory conditions. Ophthalmologic examination was also performed as a prerequisite for Valsalva maneuver for each subject.

3.3. Anthropometric and Clinical Measurements

The subjects were diagnosed as obese and treatment naïve based on complete history and physical examination, and BMI was calculated as the subject’s weight in kilograms to height in meters squared. Venous blood (5 mL) sample was collected in the morning under aseptic conditions after overnight fasting. Blood was centrifuged at 3000 rpm for 20 minutes; serum was aliquoted and stored at -80°C to analyze the metabolic parameters (fasting blood glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol, triglyceride, low-density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, and glycated hemoglobin (HbA1c).

3.4. Metabolic Parameters (Specific Laboratory Measurements)

3.4.1. CTRP3

CTRP3 was estimated using the commercial human ELISA (enzyme-linked immunosorbent assay) kit from Wuhan ELAb Science Co., Ltd. for quantitative determination of human CTRP3 in biological fluids. Assay format was 96 wells. The undiluted standard (5000 pg/mL) was recombinant protein based and the detection range of the kit was 78-5000 pg/mL. Normal CTRP3 levels ranged in plasma and serum from 0.1 to 1 µg/mL.

3.4.2. Human Adiponectin

Adiponectin was estimated using the AssayMax Human™ Adiponectin ELISA research kit by Assaypro LLC, designed to detect adiponectin in human plasma, serum, urine, milk, saliva, and cell culture supernatants. The human adiponectin standard (125 ng) in a buffered protein
A negative correlation of CTRP3 with serum triglycerides, atherogenic index, and leptin was observed in obese subjects. However, no significant correlation
Table 1. Comparison of the Study Groups in Terms of Demographic and Clinical Characteristics at Baseline

| Baseline Parameter                          | Group I Cases (N = 30) | Group II Controls (N = 30) | P Value Unpaired t-Test |
|---------------------------------------------|------------------------|---------------------------|-------------------------|
| Age, y                                      | 27.70 ± 5.34           | 27.40 ± 5.30              | 0.83                    |
| Gender, No.                                 |                        |                           |                         |
| Male                                        | 15                     | 15                        |                         |
| Female                                      | 15                     | 15                        |                         |
| Socioeconomic status (the Kuppuswamy scale) |                        |                           |                         |
| Weight, kg                                  | 87.88 ± 10.73          | 59.23 ± 7.45              | < 0.001                 |
| Height, m                                   | 1.62 ± 0.09            | 1.63 ± 0.07               | 0.57                    |
| BMI, kg/m²                                  | 33.70 ± 4.40           | 22.35 ± 1.62              | < 0.001                 |
| Systolic blood pressure, mmHg               | 118.20 ± 6.54          | 117.92 ± 6.20             | 0.99                    |
| Diastolic blood pressure, mmHg              | 84.00 ± 2.20           | 80.00 ± 3.16              | 0.99                    |
| HbA1c, %                                     | 5.51 ± 0.08            | 5.49 ± 0.09               | 0.54                    |
| TSH, mIU/L                                  | 3.39 ± 1.36            | 3.28 ± 1.13               | 0.74                    |

Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; TSH, thyroid stimulating hormone.

*P value < 0.05 was considered the level of significance.

Values are expressed as mean ± SD unless otherwise indicated.

Table 2. Comparison of Metabolic Parameters Between the Study Groups

| Metabolic Parameter                        | Group I Cases (N = 30) | Group II Controls (N = 30) | P Value Unpaired t-Test |
|--------------------------------------------|------------------------|---------------------------|-------------------------|
| Fasting blood sugar, mg/dL                 | 91.27 ± 2.56           | 84.10 ± 7.04              | < 0.001                 |
| Insulin, mIU/L                             | 9.06 ± 6.97            | 4.92 ± 1.66               | 0.001                   |
| HOMA-IR                                    | 829.96 ± 641.17        | 413.13 ± 141.33           | < 0.001                 |
| Total cholesterol, mg/dL                   | 186.90 ± 24.93         | 187.73 ± 38.78            | 0.92                    |
| HDL-cholesterol, mg/dL                     | 44.97 ± 10.19          | 53.03 ± 7.15              | < 0.001                 |
| LDL-cholesterol, mg/dL                     | 116.80 ± 20.77         | 106.67 ± 27.09            | 0.05                    |
| Triglyceride, mg/dL                        | 141.60 ± 40.41         | 94.86 ± 23.93             | < 0.001                 |
| Atherogenic index of plasma                | 0.49 ± 0.35            | 0.24 ± 0.13               | < 0.001                 |
| Total bilirubin, mg/dL                     | 0.89 ± 0.39            | 0.51 ± 0.19               | < 0.001                 |
| AST, IU/L                                  | 28.77 ± 19.44          | 30.03 ± 16.4              | 0.79                    |
| ALT, IU/L                                  | 28.77 ± 19.49          | 30.03 ± 16.40             | 0.59                    |
| ALP, IU/L                                  | 93.23 ± 20.74          | 92.93 ± 17.89             | 0.95                    |
| CTRP3, ng/mL                               | 258.22 ± 147.62        | 588.48 ± 342.64           | < 0.001                 |
| Adiponectin, ng/mL                         | 100.77 ± 31.64         | 118.50 ± 27.60            | 0.02                    |
| Leptin, pg/mL                              | 27.48 ± 8.97           | 22.79 ± 2.26              | 0.04                    |

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTRP3, C1q/TNF- related protein-3; HOMA-IR, homeostasis model assessment of insulin resistance.

*P value < 0.05 was considered the level of significance.

Values are expressed as mean ± SD.

was observed between CTRP3 and insulin or HOMA-IR (Table 3).

The comparison of various autonomic parameters between the case (group I) and controls (group II) is depicted in Table 4. There was a significant decrease in parasympathetic indices (pNN50, RMSSD, E/I ratio, 30:15 ratio, and Valsalva ratio), and an increase in sympathovagal balance (LF:HF ratio) in the subjects with obesity as compared to those of the controls, which is suggestive of a sympathetic overdrive in obesity.

A significant positive correlation of CTRP3 in obesity was observed with various parasympathetic indices.
overweight have a more favorable prognosis as compared

et al. reported an obesity paradox where they explained

gland may also express and regulate CTRP3 concentration
levels elevated with obesity, indicating that the mammary
the current study, it was reported that breast milk CTRP3
levels were positively correlated with BMI in males

et al. reported smoking, alcohol consumption, and hypertension as confounding factors in

This could be due to lower BMI and small sample size in

In the current study, decreased expression of CTRP3
was observed in subjects with obesity, which may alter the functions of various other adipokines such as adiponectin and leptin. This may contribute to dysregulation of metabolic homeostasis even in the absence of any associated co-morbid conditions. It was also observed that CTRP3 levels were inversely correlated with AIP, which is supposed to be an indicator of increased cardiovascular risk. The current study was probably the first to establish a correlation between CTRP3 and AIP.

In a recent article, contrary to the initial hypothesis of the current study, it was reported that breast milk CTRP3 levels elevated with obesity, indicating that the mammary gland may also express and regulate CTRP3 concentration in breast milk (29). Another recent research by Sawicka et al. reported an obesity paradox where they explained that although obesity is a risk factor for cardiovascular diseases, in case of heart failure, patients with obesity and overweight have a more favorable prognosis as compared to patients with normal body weight. They explained it partly by a positive effect of adipokines including CTRP3 produced by adipose tissue, particularly by the tissue located in the direct vicinity of the heart and blood vessels (30). It was contradictory to the previously known fact that the expression and production of CTRP3 significantly reduces in post-myocardial infarction (MI) patients and replenishment of CTRP3 protects the heart by attenuating post-ischemic pathologic remodeling and promoting cardiomyocyte-endothelial cell communication (4). These conflicting results can be explained by the fact that all of these studies examined the total level of CTRP3, but not considering the different splice variants or the multi-meric structures of the circulating CTRP3. The high-order oligomeric complexes of CTRP3 occur solely between its two splice variants, CTRP3A and CTRP3B (31). Moreover, lysosomal-associated membrane proteins 1 and 2 (LAMP 1 and LAMP 2) are identified as receptors for CTRP3, both being widely expressed in a number of different tissue involved in a variety of functions attributed to CTRP3 (31). Since CTRP3 is endogenously co-expressed in many tissues with other proteins within the Ctg/TNF superfamily, it may diversify functions and is likely to modify the function of CTRP3. Further research is required to understand the diversified molecular functions of CTRP3.

In the current study, decreased expression of CTRP3 was observed in subjects with obesity, which may alter the functions of various other adipokines such as adiponectin and leptin. This may contribute to dysregulation of metabolic homeostasis even in the absence of any associated co-morbid conditions. It was also observed that CTRP3 levels were inversely correlated with AIP, which is supposed to be an indicator of increased cardiovascular risk. The current study was probably the first to establish a correlation between CTRP3 and AIP.

5. Discussion

The findings of the current study suggested that serum CTRP3 levels significantly reduced in subjects with obesity. However, the reported associations between obesity and CTRP3 levels are contradictory in literature. According to literature, CTRP3 levels is elevated, showed no changes, or even reduced with obesity (3, 17-20, 25-27). Although previous studies support that BMI was a significant predictor of CTRP3 levels (3, 19, 20, 25, 26), the current study data indicated no significant correlation between CTRP3 and BMI, considering a mean BMI of 33.70 ± 4.40 kg/m² in the group I (classification of obesity by WHO for Asian population). This could be due to lower BMI and small sample size in the current study. In most of the previous studies, varying proportions of male and female subjects were selected (3, 20, 21, 26, 28). The number of male and female subjects was equal in group I- the current study obese cases- and the obtained results on gender did not show any gender predilection for CTRP3 levels. Deng et al. reported smoking, alcohol consumption, and hypertension as confounding factors in obesity (25), while Wagner et al. found no significant correlation of CTRP3 levels in cases with coronary artery disease, dyslipidemia, hypertension, or tobacco use, but their CTRP3 levels were positively correlated with BMI in males and negatively correlated with BMI in female subjects (26).

In a recent article, contrary to the initial hypothesis of the current study, it was reported that breast milk CTRP3 levels elevated with obesity, indicating that the mammary gland may also express and regulate CTRP3 concentration in breast milk (29). Another recent research by Sawicka et al. reported an obesity paradox where they explained that although obesity is a risk factor for cardiovascular diseases, in case of heart failure, patients with obesity and overweight have a more favorable prognosis as compared to patients with normal body weight. They explained it partly by a positive effect of adipokines including CTRP3 produced by adipose tissue, particularly by the tissue located in the direct vicinity of the heart and blood vessels (30). It was contradictory to the previously known fact that the expression and production of CTRP3 significantly reduces in post-myocardial infarction (MI) patients and replenishment of CTRP3 protects the heart by attenuating post-ischemic pathologic remodeling and promoting cardiomyocyte-endothelial cell communication (4). These conflicting results can be explained by the fact that all of these studies examined the total level of CTRP3, but not considering the different splice variants or the multi-meric structures of the circulating CTRP3. The high-order oligomeric complexes of CTRP3 occur solely between its two splice variants, CTRP3A and CTRP3B (31). Moreover, lysosomal-associated membrane proteins 1 and 2 (LAMP 1 and LAMP 2) are identified as receptors for CTRP3, both being widely expressed in a number of different tissue involved in a variety of functions attributed to CTRP3 (31). Since CTRP3 is endogenously co-expressed in many tissues with other proteins within the Ctg/TNF superfamily, it may diversify functions and is likely to modify the function of CTRP3. Further research is required to understand the diversified molecular functions of CTRP3.

In the current study, decreased expression of CTRP3 was observed in subjects with obesity, which may alter the functions of various other adipokines such as adiponectin and leptin. This may contribute to dysregulation of metabolic homeostasis even in the absence of any associated co-morbid conditions. It was also observed that CTRP3 levels were inversely correlated with AIP, which is supposed to be an indicator of increased cardiovascular risk. The current study was probably the first to establish a correlation between CTRP3 and AIP.

To the best of authors knowledge, this is also probably the first study to correlate the CTRP3 levels with the results of autonomic function tests and heart rate variability. The presence of cardiac autonomic dysfunction is considered when at least one parasympathetic test result is abnormal, irrespective of a gynoid or android type of obesity (32). A significantly higher LF:HF ratio in the frequency domain and lowered values of pNN50 and RMSSD in the time domain indices of HRV represented a reduced vagal tone in subjects with obesity in the current study. The significant positive correlation of CTRP3 with parasympathetic indices (pNN50 and 30:15 ratio), and an inverse correlation between CTRP3 and sympathovagal LF/HF ratio in the current study also suggested that with decreasing CTRP3 levels in obesity, the sympathetic overdrive in the body increases. The lesser the CTRP3 levels, the greater the HRV may be unfavorable for the body. Thus, CTRP3 is a cardioprotective adipokine that may play an important role in pathophys-

Table 3. Correlation of CTRP3 with Metabolic Parameters in Subjects with Obesity

| Variable                  | r Value | P Value |
|---------------------------|---------|---------|
| BMI, kg/m²                | -0.22   | 0.24    |
| Adiponectin, ng/ml        | 0.42    | 0.02    |
| Leptin, pg/ml             | -0.39   | 0.02    |
| Insulin, mIU/L            | 0.10    | 0.57    |
| HOMA-IR                   | 0.65    | 0.62    |
| Triglyceride, mgidl.      | -0.09   | < 0.001 |
| Atherogenic index of plasma | -0.37  | 0.04    |

Abbreviations: BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance.

* P value < 0.05 was considered as the level of significance.
Table 4. Comparison of Heart Rate Variability with Autonomic Parameters Between the Study Groups

| Variables                  | Group I Cases (N = 30) | Group II Control (N = 30) | P Value Unpaired t-Test |
|----------------------------|------------------------|---------------------------|-------------------------|
| HRV parameter              |                        |                           |                         |
| RMSSD                      | 25.91 ± 15.06          | 56.30 ± 27.09             | < 0.001                 |
| pNN50                      | 6.42 ± 11.34           | 31.79 ± 19.42             | < 0.001                 |
| LF                         | 135.81 ± 404           | 38.38 ± 8.06              | 0.20                    |
| HF                         | 74.35 ± 202.56         | 59.56 ± 7.62              | 0.70                    |
| LF/HF ratio                | 1.77 ± 0.54            | 0.67 ± 0.18               | < 0.001                 |
| Parasympathetic function tests |                      |                           |                         |
| E:I ratio                  | 1.35 ± 0.27            | 1.52 ± 0.23               | 0.02                    |
| 30:15 ratio                | 1.31 ± 0.12            | 1.45 ± 0.17               | 0.003                   |
| Valsalva ratio             | 2.09 ± 0.83            | 1.66 ± 0.26               | 0.01                    |
| Sympathetic function tests |                        |                           |                         |
| Lying to standing test (SBP in mmHg) | 7.87 ± 0.57 | 8.30 ± 0.95 | 0.08                   |
| Sustained handgrip test (DBP in mmHg) | 21.77 ± 7.01 | 21.80 ± 4.59 | 0.98                   |
| Cold pressor test (DBP in mmHg) | 21.87 ± 6.44 | 22.13 ± 6.28 | 0.77                   |

Abbreviations: 30:15 ratio, quotient of the maximal (around 30th heart beat) to minimal (near 15th heart beat) RR interval; CPT, cold pressor test; DBP, diastolic blood pressure; E:I ratio, ratio of the longest RR interval during expiration and the shortest RR interval during inspiration; HF, high frequency; LF, low frequency; LST, lying to standing test; pNN50, proportion of differences in consecutive NN intervals that are longer than 50 ms; RMSSD, square root of mean squared difference of successive NN intervals; SBP, systolic blood pressure; SHT, sustained handgrip test.

Table 5. Correlation of CTRP3 With Heart Rate Variability and Autonomic Parameters in the Study Groups

| Variable                  | r Value | P Value |
|---------------------------|---------|---------|
| Heart rate variability    |         |         |
| RMSSD                     | 0.15    | 0.42    |
| pNN50                     | 0.17    | 0.05    |
| LF                        | -0.27   | 0.13    |
| HF                        | 0.25    | 0.17    |
| LF/HF ratio               | -0.35   | 0.05    |
| Parasympathetic function tests |          |         |
| E:I ratio                 | 0.02    | 0.88    |
| 30:15 ratio               | 0.62    | < 0.01  |
| Valsalva ratio            | 0.14    | 0.30    |
| Sympathetic function tests |         |         |
| Lying to standing test (SBP in mmHg) | -0.30   | 0.09    |
| Sustained handgrip test (DBP in mmHg) | -0.04   | 0.80    |
| Cold pressor test (DBP in mmHg) | -0.06   | 0.74    |

Abbreviations: 30:15 ratio, quotient of the maximal (around 30th heart beat) to minimal (near 15th heart beat) RR interval; CPT, cold pressor test; DBP, diastolic blood pressure; E:I ratio, ratio of the longest RR interval during expiration and the shortest RR interval during inspiration; HF, high frequency; LF, low frequency; LST, lying to standing test; pNN50, proportion of differences in consecutive NN intervals that are longer than 50 ms; RMSSD, square root of mean squared difference of successive NN intervals; SBP, systolic blood pressure; SHT, sustained handgrip test.

No significant correlation was observed between CTRP3 and insulin or HOMA-IR in the current study; although the levels of insulin and HOMA-IR significantly
raised in group I. In previous studies, CTRP3 reduced inflammation by improving the insulin signaling transduction and insulin sensitivity of IR 3T3-L1 in adipocytes (33, 34). CTRP3 may also exert its effect through adiponectin-like AMPK (5'AMP-activated protein kinase) insulin signaling pathways (as they bear structural homology to PPAR-γ) mediated pathway (35). Further studies are needed to determine signal transduction and molecular mechanisms supporting this hypothesis in order to link CTRP3, insulin sensitivity, and obesity.

One of the strengths of the current study was the inclusion and exclusion criteria designed to exclude the confounding factors that might alter CTRP3 levels, unlike most of the previous other studies. Moreover, autonomic function tests and their correlation with CTRP3 in obesity are not studied much. Hence, CTRP3 may be considered as a potential biomarker to develop therapeutic interventions and molecular targeted strategies to improve health and decrease risks associated with obesity.

Smaller sample size, type and sensitivity of antibodies used in ELISA, or a lower mean BMI for obesity as compared to previous studies could be certain limitations of the current study. Further analyses and larger sample sizes are needed to interpret this conflicting gender-dependent association of obesity and circulating CTRP3 levels.

5.1. Conclusions

Higher circulating levels of CTRP3 may promote a favorable autonomic and metabolic profile in obesity. Hence, CTRP3 may prove a potential novel biomarker to facilitate the prognosis of obesity and its co-morbidities.

Footnotes

Authors’ Contribution: Study concept and design: Asha Yadav and Neha Bindlish Jain; acquisition of data: Neha Bindlish Jain, Asha Yadav, Nilima Shankar, and Rafat Ahmed; analysis and interpretation of data: Statistics Department of UCMS; drafting of the manuscript: Asha Yadav and Neha Bindlish Jain; critical revision of the manuscript for important intellectual content: Nilima Shankar and Rafat Ahmed; administrative, technical, and material support: Nilima Shankar and Asha Yadav; study supervision: Asha Yadav, Nilima Shankar, and Rafat Ahmed.

Conflict of Interests: The authors declared no conflict of interests.

Ethical Approval: Ethical clearance was obtained for the study from the Institutional Research Protocol and Ethics Committee Board.

Financial Disclosure: Authors declared no financial disclosure.

Funding/Support: The project was financially supported by the local university.

Patient Inform: Written informed consent explaining the duration, type, and objectives of the study was obtained from all subjects.

References

1. Schaffer A, Scholmerich J, Salzberger B. Adipose tissue as an immunological organ: Toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol. 2007;28(9):393–9. doi: 10.1016/j.it.2007.07.001. [PubMed: 17681884].
2. Schmid A, Kopp A, Hanses F, Karrasch T, Schaffer A. C1q/TNF-related protein-3 (CTRP-3) attenuates lipopolysaccharide (LPS)-induced systemic inflammation and adipose tissue Erk-1/-2 phosphorylation in mice in vivo. Biochem Biophys Res Commun. 2004;325(1):8–13. doi: 10.1016/j.bbrc.2004.06.054. [PubMed: 14996712].
3. Wolf RM, Steele KE, Peterson LA, Magnuson TH, Schweitzer MA, Wong GW. Lower circulating C1q/TNF-related protein-3 (CTRP3) levels are associated with obesity: A cross-sectional study. PLoS One. 2015;10(7). doi: 10.1371/journal.pone.0139508.
4. Yi W, Sun Y, Yuan Y, Lau WB, Zheng Q, Wang X, et al. C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation. 2012;125(25):3159–69. doi: 10.1161/CIRCULATIONAHA.112.999337. [PubMed: 22653084]. [PubMed Central: PMC3591313].
5. Seldin MM, Tan SY, Wong GW. Metabolic function of the CTRP family of hormones. Rev Endocr Metab Disord. 2014;15(2):111–23. doi: 10.1007/s11154-013-9255-7. [PubMed: 23963681]. [PubMed Central: PMC391758].
6. Schaffer A, Buechler C. CTRP family: Linking immunity to metabolism. Trends Endocrinol Metab. 2012;23(4):194–204. doi: 10.1016/j.tem.2011.12.001. [PubMed: 22261910].
7. Smith MM, Minson CT. Obesity and adipokines: Effects on sympathetic overactivity. J Physiol. 2012;590(6):879–801. doi: 10.1113/jphysiol.2011.221016. [PubMed: 22235630]. [PubMed Central: PMC3573103].
8. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation. 1997;96(10):3423–9. doi: 10.1161/01.CIR.96.10.3423. [PubMed: 9396437].
9. Hirsch J, Leibel RL, Mackintosh R, Aguirre A. Heart rate variability as a measure of autonomic function during weight change in humans. Am J Physiol. 1991;261(6 Pt 2):R848–53. doi: 10.1152/ajpregu.1991.261.6.R848. [PubMed: 17505566].
10. Petretta M, Bonaduce D, de Filippo E, Mureddu GF, Scalfi L, Marziano F, et al. Assessment of cardiac autonomic control by heart period variability in patients with early-onset familial obesity. Eur J Clin Invest. 1995;25(11):826–32. doi: 10.1111/j.1365-2362.1995.tb01691.x. [PubMed: 8522447].
11. Straznicky NE, Eikelis N, Lambert EA, Esler MD. Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep. 2010;12(6):440–7. doi: 10.1007/s11906-008-0083-4. [PubMed: 18959829].
12. Kurajoh M, Koyama H, Kadoya M, Naka M, Miyoshi A, Kanzaki A, et al. Plasma leptin level is associated with cardiac autonomic dysfunction in patients with type 2 diabetes: HSCAA study. Cardiovasc Diabetol. 2015;14:117. doi: 10.1186/s12933-015-0280-6. [PubMed: 26318087]. [PubMed Central: PMC4560077].
13. Van De Wielle R, Michels N. Longitudinal associations of leptin and adiponectin with heart rate variability in children. Front Physiol. 2017;8:498. doi: 10.3389/fphys.2017.00498. [PubMed: 28747890]. [PubMed Central: PMC5069193].
14. Charles LE, Burchiel CM, Sarkissian K, Li S, Miller DB, Gu JK, et al. Leptin, adiponectin, and heart rate variability among police officers.
Am J Hum Biol. 2015;27(2):184–91. doi: 10.1002/ajhb.22636. [PubMed: 25270216]. [PubMed Central: PMC4699294].

15. Pietersen C, Schute R, Schute AE. Autonomic activity and leptin in Africans and whites: The SABPA study. J Hypertens. 2014;32(4):826–33. doi: 10.1097/HJH.0000000000000410. [PubMed: 24599221].

16. Malik M, Bigger JT, Camm AJ, Kleiger RE, Matalanis A, Moss AJ, et al. Heart rate variability: Standards of measurement, physiological interpretation, and clinical use. Eur Heart J. 1996;17(1):354–81. doi: 10.1093/oxfordjournals.eurheartj.a048688. [PubMed: 8737210].

17. Tan BK, Chen J, Hu J, Amar O, Matsu HS, Adya R, et al. Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(12):E1897–900. doi: 10.1210/jc.2013-2227. [PubMed: 24342661].

18. Choi HY, Park JW, Lee N, Hwang SY, Cho GJ, Hong HC, et al. Implications of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13:8. doi: 10.1186/1472-6823-13-8. [PubMed Central: PMC4277445].

19. Choi HY, Park JW, Lee N, Hwang SY, Cho GJ, Hong HC, et al. Effects of a combined aerobic and resistance exercise program on Cigf/TNF-related protein-3 (CTRP-3) and CTRP-5 levels. Diabetes Care. 2013;36(10):3321–7. doi: 10.2337/dc13-0178. [PubMed: 23780948]. [PubMed Central: PMC3781543].

20. Choi KM, Hwang SY, Hong HC, Yang SJ, Choi DS, et al. Implication of programulin and Cigf/TNF-related protein-3 (CTRP-3) on inflammation and atherosclerosis in subjects with or without metabolic syndrome. PLoS One. 2013;8(2). doi: 10.1371/journal.pone.0055744.

21. Wen CP, David Cheng TY, Tsai SP, Chan HT, Hsu HL, Hsu CC, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: Effect on CTRP3, PEDF concentrations in patients with type 2 diabetes and C1q/TNF-related protein-3 (CTRP-3) levels are decreased in obesity and hyper-tension and are negatively correlated with parameters of insulin resistance. Diabetol Metab Syndr. 2015;7:33. doi: 10.1186/s13226-015-0029-0. [PubMed: 25487729]. [PubMed Central: PMC4397728].

22. Wagner RM, Swagmanam K, Clark WA, Peterson JM. Divergent relationship of circulating CTRP3 levels between obesity and gender: A cross-sectional study. PeerJ. 2016;4. e2573. doi: 10.7717/peerj.4272. [PubMed: 27781187]. [PubMed Central: PMC5075694].

23. Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya J, et al. The SABPA study. Afr J Health Sci. 2014;21(2):184–91. doi: 10.4314/ajhs.v21i2.13. [PubMed: 23780948]. [PubMed Central: PMC3478553].

24. Chaudhuri R. Autonomic failure. A textbook of clinical disorders of the autonomic nervous system: Edited by Christopher J Mathias and Sir Roger Bannister. Oxford: Oxford University Press; 2002. doi: 10.1136/jnnp.74.4.551.

25. Deng W, Li C, Zhang Y, Zhao J, Yang M, Tian M, et al. Serum Cigf/TNF-related protein-3 (CTRP3) levels are decreased in obesity and hypertension and are negatively correlated with parameters of insulin resistance. Diabetol Metab Syndr. 2015;7:33. doi: 10.1186/s13226-015-0029-0. [PubMed: 25487729]. [PubMed Central: PMC4397728].